1,112
Views
4
CrossRef citations to date
0
Altmetric
Editorial

Differential diagnosis of depressive illness versus intense normal sadness: how significant is the ‘clinical significance criterion’ for major depression?

, &
Pages 1015-1018 | Published online: 09 Jan 2014

References

  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition – Text Revision. American Psychiatric Publishing, DC, USA (2000).
  • Spitzer RL, Wakefield JC. DSM-IV diagnostic criterion for clinical significance: Does it help solve the false positives problem? Am. J. Psychiatry156, 1856–1864 (1999).
  • Moffitt TE, Caspi A, Taylor A et al. How common are common mental disorders? Evidence that lifetime prevalence rates are doubled by prospective versus retrospective ascertainment. Psychol. Med.40(6), 899–909 (2010).
  • Frances A. Problems in defining clinical significance in epidemiological studies. Arch. Gen. Psychiatry55(2), 119 (1998).
  • Wakefield JC, Schmitz MF, Baer JC. Does the DSM-IV clinical significance criterion for major depression reduce false positives? Evidence from the National Comorbidity Survey replication. Am. J. Psychiatry167, 298–304 (2010).
  • Kessler RC, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry62, 593–602 (2005).
  • Kessler RC, McGonagle KA, Zhao SN et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch. Gen. Psychiatry51, 8–19 (1994).
  • Wakefield JC. Disorder as harmful dysfunction: a conceptual critique of DSM-III-R’s definition of mental disorder. Psychol. Rev.99(2), 232–247 (1992).
  • Wakefield JC. The concept of mental disorder: on the boundary between biological facts and social values. Am. Psychol.47(3), 373–388 (1992).
  • Horwitz AV, Wakefield JC. The Loss of Sadness: How Psychiatry Transformed Normal Sorrow into Depressive Disorder. Oxford University Press, NY, USA (2007).
  • Schneider ME. DSM-V Task Force weighing changes. Clin. Psychiatry News37(4), 1 (2009).
  • World Health Organization. International Statistical Classification of Diseases and Related Health Problems (Tenth revision [ICD-10]). WHO, Geneva, Switzerland (1994).
  • Nicol CF. Depression viewed through neurologic spectacles. Psychosomatics9, 252–254 (1968).
  • Gauthier A, Vignola A, Calvo A et al. A longitudinal study on quality of life and depression in ALS patient-caregiver couples. Neurology68, 923–926 (2007).
  • Jackson SW. Melancholia and Depression: From Hippocratic Times to Modern Times. Yale University Press, CT, USA (1986).
  • Niedemaier N, Bohrer E, Schulte K et al. Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J. Clin. Psychiatry65, 1619–1623 (2004).
  • Fruehald S, Gatterbauer E, Rehak P et al. Early fluoxetine treatment of post-stroke depression – a three-month double-blind placebo-controlled study with an open-abel long-term follow-up. J. Neurol.250, 347–351 (2003).
  • Jannsens AC, van Doorn PA, de Boer JB et al. Perception of prognostic risk in patients with multiple sclerosis: the relationship with anxiety, depression and disease related distress. J. Clin. Epidemiol.57, 180–186 (2004).
  • Jopson NM, Moss-Morris R. The role of illness severity and illness representations in adjusting to multiple sclerosis. J. Psychosom. Res.54, 503–511 (2003).
  • Sobel RM, Latkowski S, Mandel S. Update on depression in neurologic illness: stroke, epilepsy, and multiple scleroses. Curr. Psychiatry Rep.7, 396–403 (2005).
  • Feinstein A, O’Connor P, Akbar N et al. Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Mult. Scler.16(2), 189–196 (2010).
  • Albert SM, Rabkin JG, Del Bene ML et al. Wish to die in end-stage ALS. Neurology65, 68–74 (2005).
  • Williams LS, Jones WJ, Shen RL et al. Prevalence and impact of depression and pain in neurology outpatients. J. Neurol. Neurosurg. Psychiatry74(11), 1587–1589 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.